Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
PF-610355
Другие языки:

PF-610355

Подписчиков: 0, рейтинг: 0
PF-610355
PF-610355.svg
Clinical data
Routes of
administration		 Inhalation
ATC code
  • None
Legal status
Legal status
  • Development terminated
Identifiers
  • N-[(4'-Hydroxy-3-biphenylyl)methyl]-2-[3-(2-{[(2R)-2-hydroxy-2-{4-hydroxy-3-[(methylsulfonyl)amino]phenyl}ethyl]amino}-2-methylpropyl)phenyl]acetamide
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
Chemical and physical data
Formula C34H39N3O6S
Molar mass 617.76 g·mol−1

PF-610355 (also known as PF-00610355 or PF-610,355) is an inhalableultra-long-acting β2 adrenoreceptor agonist (ultra-LABA) that was investigated as a treatment of asthma and COPD by Pfizer. It utilizes a sulfonamide agonist headgroup, that confers high levels of intrinsic crystallinity that could relate to the acidic sulfonamide motif supporting a zwitterionic form in the solid state. Optimization of pharmacokinetic properties minimized systemic exposure following inhalation and reduced systemically-mediated adverse events. Its in vivo duration on action confirmed its potential for once-daily use in humans.

The investigation and development of PF-610355 were discontinued in 2011, likely for strategic and regulatory reasons.


Новое сообщение